etodolac has been researched along with Keratoconjunctivitis Sicca in 3 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Keratoconjunctivitis Sicca: Drying and inflammation of the conjunctiva as a result of insufficient lacrimal secretion. When found in association with XEROSTOMIA and polyarthritis, it is called SJOGREN'S SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs." | 7.74 | Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). ( Crawford, DA; Fitzgerald, KE; Giuliano, EA; Klauss, G; Martin, SL; Moore, CP; Stuhr, CM; Tyler, JW, 2007) |
| "To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs." | 3.74 | Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). ( Crawford, DA; Fitzgerald, KE; Giuliano, EA; Klauss, G; Martin, SL; Moore, CP; Stuhr, CM; Tyler, JW, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stiles, J | 1 |
| Hampshire, VA | 1 |
| Doddy, FM | 1 |
| Post, LO | 1 |
| Koogler, TL | 1 |
| Burgess, TM | 1 |
| Batten, PO | 1 |
| Hudson, R | 1 |
| McAdams, DR | 1 |
| Brown, MA | 1 |
| Klauss, G | 1 |
| Giuliano, EA | 1 |
| Moore, CP | 1 |
| Stuhr, CM | 1 |
| Martin, SL | 1 |
| Tyler, JW | 1 |
| Fitzgerald, KE | 1 |
| Crawford, DA | 1 |
3 other studies available for etodolac and Keratoconjunctivitis Sicca
| Article | Year |
|---|---|
Warning of an adverse effect of etodolac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Keratoconjunctivitis | 2004 |
Adverse drug event reports at the United States Food And Drug Administration Center for Veterinary Medicine.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Stero | 2004 |
Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002).
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac | 2007 |